Homocysteine, a new cardiovascular risk factor, is also a powerful uremic toxin

Journal of Nephrology

Volumn 12, Issue 4, 1999, Pages 230-240

  Perna, Alessandra F ^a   Castaldo, Pasquale ^a   Ingrosso, Diego ^a   De Santo, Natale G ^a  

^a Special Section of Surgical Digestive Endoscopy   (Italy)

Author keywords

Atherosclerosis; Homocysteine; Transmethylations; Uremic toxin

Indexed keywords

ACETYLCYSTEINE; BETAINE; CYANOCOBALAMIN; CYSTATHIONINE; FOLIC ACID; HOMOCYSTEINE; LEVODOPA; METHIONINE; METHOTREXATE; METHYLTRANSFERASE; NICOTINIC ACID; NITROUS OXIDE; PYRIDOXINE; S ADENOSYLHOMOCYSTEINE; S ADENOSYLMETHIONINE; THEOPHYLLINE; UREMIC TOXIN;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; DIET; DRUG INDUCED DISEASE; ENZYME INHIBITION; GENETIC PREDISPOSITION; HEMODIALYSIS; HOMOCYSTINURIA; HYPERHOMOCYSTEINEMIA; METABOLIC DISORDER; REVIEW; UREMIA;

ANIMALS; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; HOMOCYSTEINE; HOMOCYSTINURIA; HUMANS; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE, CHRONIC; RISK FACTORS;

EID: 0032853562     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (121)

1. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of atherosclerosis. Am J Pathol 1969;56:111-28.
2. Refsum H, Ueland PM. Recent data are not in conflict with homocysteine as a cardiovascular risk factor. Curr Opin Lipidol 1998; 9: 533-9.
3. Refsum H, Ueland PM, Nygård O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med 1998; 49: 31-62.
4. Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med 1998; 158: 2101-6.
5. Dennis VW, Nurko S, Robinson K. Hyperhomocysteinemia: detection, risk assessment, and treatment. Curr Opin Nephrol Hypertens 1997; 6: 483-8.
6. Kang SS, Wong PWK, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Ann Rev Nutr 1992; 12: 279-98.
7. Mudd S H, Levy H L, Skovby F. Disorders of transsulfuration. In: Scriver C R, Beaudet A L, Sly W S, Valle D, eds. The metabolic basis of inherited disease. New York: Mc Graw Hill 1989; 693-737.
8. Stamler JS, Slivka A. Biological chemistry of thiols in the vasculature and in vascular-related disease. Nutr Rev 1996; 54: 1-30.
9. Zappia V, Zydek-Cwick CR, Schlenk F. The specificity of S-adenosylmethionine derivatives in methyl transfer reactions. J Biol Chem 1969; 244: 4499-505.
10. Cantoni GL, Richards HH, Chiang PK. Inhibitors of S-adenosylhomocysteine hydrolase and their role in the regulation of biological methylation. In: Usdin E, Borchard RT, Creveling CR, eds. Transmethylations. North Holland, Amsterdam: Elsevier 1979; 155-64.
11. Cantoni G L, Chiang P K. The role of S-adenosylhomocysteine and S-adenosylhomocysteine hydrolase in the control of biologic methylations. In: Cavallini D, Gaull G E, Zappia V, eds. Natural Sulfur Compounds: Novel Biochemical and Structural Aspects. New York: Plenum Press 1980; 67-89.
12. Barber J R, Clarke S. Inhibition of protein carboxyl methylation by S-adenosyl-L homocysteine in intact erythrocytes. Physiological consequences. J Biol Chem 1984; 259: 7115-22.
13. Cantoni G L. The centrality of S-adenosylhomocysteinase in the regulation of the biological utilization of S-adenosylmethionine. In: Borchardt R T, Creveling C R, Ueland P M, Clifton NJ, eds. Biological methylation and drug design. Experimental and clinical roles of S adenosylmethionine. Humana Press 1986; 227-38.
14. Galletti P, Ingrosso D, Manna C, Clemente G, Zappia V. Protein damage and methylation mediated repair in the erythrocyte. Biochem J 1995; 306: 313-25.
15. McKeever M, Molloy A, Weir DG, et al. An abnormal methylation ratio induces hypomethylation in vitro in the brain of pig and man but not in rat. Clin Sci 1995; 88: 73-9.
16. Selhub J, Miller J W. The pathogenesis of homocysteinemia: interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr 1992; 55: 131-8.
17. Bostom AG, Jacques PF, Nadeau MR, Williams RR, Ellison RC, Selhub J. Post-methionine load hyperhomocysteinemia in persons with normal fasting total plasma homocysteine: initial results from the NHLBI Family Heart Study. Atherosclerosis 1995; 116: 147-51.
18. Cattaneo M, Lombardi R, Lecchi A, Zighetti ML. Is the oral methionine loading test insensitive to the remethylation pathway of homocysteine? Blood 1999; 93: 1118-20.
19. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: A common mutation in the methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-3.
20. Brattstrom L, Zhang Y, Hurtig M, et al. A common methylenetetrahydrofolate reductase gene mutation and longevity. Atherosclerosis 1998; 141: 315-9.
21. Sperandeo MP, de Franchis R, Andria G, Sebastio G. A 68-bp insertion found in a homocystinuric patient is a common variant and is skipped by alternative splicing of the cystathionine beta-synthase mRNA. Am J Hum Genet 1996; 59: 1391-3.
22. Tsai MY, Bignell M, Schwichtenberg K, Hanson NQ. High prevalence of a mutation in the cystathionine beta-synthase gene. Am J Hum Genet 1996; 59: 1262-7.
23. Kluijtmans LA, Boers GH, Trijbels FJ, van Lith-Zanders HM, van den Heuvel LP, Blom HJ. A common 844INS68 insertion variant in the cystathionine beta-synthase gene. Biochem Mol Med 1997; 62: 23-5.
24. Herbert V. Recommended dietary intakes (RDI) of folate in humans. Am J Clin Nutr 1987; 45: 661-70.
25. Andersson A, Isaksson A, Brattstrom L, Israelsson B, Hultberg B. Influence of hydrolysis on plasma homocysteine determination in healthy subjects and patients with myocardial infarction. Atherosclerosis 1991; 88: 143-51.
26. Stehouwer CD, Gall MA, Hougaard P, Jakobs C, Parving HH. Plasma homocysteine concentration predicts mortality in non-insulin-dependent diabetic patients with and without albuminuria. Kidney Int 1999; 55: 308-14.
27. Wilcken DEL, Gupta V J, Reddy SG. Accumulation of sulfur-containing amino acids including cysteine-homocysteine in patients on maintenance haemodialysis. Clin Sci 1980; 58: 427-30.
28. Laidlaw S A, Smolin L A, Davidson W D, Kopple J D. Sulfur amino acids in maintenance hemodialysis patients. Kidney Int 1987; 32: S191-S196.
29. Chauveau P, Chadefaux B, Coudé M, et al. Increased plasma homocysteine concentration in patients with chronic renal failure. Miner Electrolyte Metab 1992; 18:196-8.
30. Chauveau P, Chadefaux B, Coudé M, et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 1993; 43: S72-S77.
31. Hultberg B, Andersson A, Sterner G. Plasma homocysteine in renal failure. Clin Nephrol 1993; 40: 230-5.
32. Bachmann J, Tepel M, Raidt H, et al. Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 1995; 6: 121-5.
33. Robinson K, Gupta A, Dennis V, et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and piridoxine concentrations. Circulation 1996; 94: 2743-8.
34. Dennis V W, Robinson K. Homocysteinemia and vascular disease in end stage renal disease. Kidney Int 1996; 50(57): S11-S17.
35. Gupta A, Robinson K. Hyperhomocysteinaemia and end stage renal disease. J Nephrol 1997; 10: 77-84.
36. Bostom AG, Lathrop L. Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 1997; 52: 10-20.
37. Tsai MY, Welge BG, Hanson NQ, et al. Genetic causes of mild hyperhomocysteinemia in patients with premature occlusive coronary artery diseases. Atherosclerosis 1999; 143: 163-70.
38. Wilcken DEL, Wilcken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest 1976; 57: 1079-82.
39. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-55.
40. Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The atherosclerosis risk in communities study. Circulation 1993; 87: 1107-13.
41. Nygard O, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland homocysteine study. JAMA 1995; 274: 1526-33.
42. Robinson K, Mayer EL, Miller DP, et al. Hyperhomocysteinemia and low pyridoxal phosphate: common and independent reversible risk factors for coronary artery disease. Circulation 1995; 92: 2825-30.
43. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995; 274: 1049-57.
44. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease: The European Concerted action Project. JAMA 1997; 277: 1775-81.
45. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992; 268: 877-81.
46. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaung JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995; 24: 704-9.
47. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995; 346: 1395-8.
48. Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM. Homocysteine and ischemic heart disease. Results of a prospective study with implications regarding prevention. Arch Intern Med 1998; 158: 862-7.
49. Bots ML, Launer LJ, Lindemans J, Hoes AW, Hofman A, Witteman JC, Koudstaal PJ, Grobbee DE. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study. Arch Intern Med 1998; 159: 38-44.
50. Chasan-Taber L, Selhub J, Rosenberg IH, Malinow MR, Terry P, Tishlet PV, Willett W, Hennekens CH, Stampfer MJ. A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians. J Am Coll Nutr 1996; 15: 136-43.
51. Rimm EB, Willett WC, Hu FB, et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998; 279: 359-64.
52. Verhoef P, Hennekens CH, Allen RH, Stabler SP, Willett WC, Stamfer MJ. Plasma total homocysteine and risk of angina pectoris with subsequent coronary artery bypass surgery. Am J Cardiol 1997; 79: 799-801.
53. Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Willett WC, Stamfer MJ. A prospective study of plasma homocysteine and risk of ischemic stroke. Stroke 1994; 25: 1924-30.
54. Alfthan G, Pekkanen J, Jauhiainen M, et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1990; 106: 9-19.
55. Folsom AR, Nieto FJ, McGovern PG, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphism, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 1998; 98: 204-10.
56. Evans RW, Shaten BJ, Hempel JD, Cutler JA, Kuller LH. Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol 1997; 17: 1947-53.
57. Nygard O, NordrehaugJE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-6.
58. Andersson A, Isakson A, Hultberg B. Homocysteine export from erythrocytes and its implication for plasma sampling. Clin Chem 1992; 38: 1311-5.
59. Ubbink J B, Vermaak W J H, Bissbort S. Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr 1991; 565: 441-6.
60. Accinni R, Campoli J, Bartesaghi S, De Leo G, Lucarelli C, Cursano CF, Parodi O. High performance liquid chromatographic determination of total plasma homocysteine with or withour internal standards. J Chromatogr 1998; 828: 397-400.
61. Brattstrom LE. Common mutation in the methylenetetrahydrofolate reductase gene offers no support for mild hyperhomocysteinemia being a causal risk factor for cardiovascular disease. Circulation 1997; 96: 3805-7.
62. Wilcken DE, Wang XL, Wilken B. Methylenetetrahydrofolate reductase (MTHFR) mutation, homocyst(e)ine, and coronary artery disease. Circulation 1997; 96: 2738-40.
63. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N EnglJ Med 1998; 338: 1042-50.
64. Jakubowski H. Metabolism of homocysteine thiolactone in human cell cultures: possible mechanisms for pathological consequences of elevated homocysteine levels. J Biol Chem 1997; 272: 1935-42.
65. Antonio CM, Nunes MC, Refsum H, Abraham AK. A novel pathway for the conversion of homocysteine to methionine in eucaryotes. Biochem J 1997; 328: 165-70.
66. Tsai C, Perrella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994; 91: 6369-73.
67. Harpel PC, Chang VT, Bort W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: A potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Nad Acad Sci USA 1992; 89: 10193-7.
68. Preibisch G, Kuffner, Elstner EF. Biochemical model reactions on the prooxidative activity of homocysteine. J Biosciences 1992; 48c: 58-62.
69. Rodgers GM, Kane WH. Activation of endogenous Factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest 1986; 77: 1909-16.
70. Hayashi T, Honda G, Suzuki K. An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells. Blood 1992; 79: 2930-6.
71. ras methylation in vascular endothelial cells by homocysteine but not cysteine. J Biol Chem 1997; 272: 25380-5.
72. Brude IR, Finstad HS, Seljeflot I, Drevon CA, Solvoll K, Sandstad B, Hjermann I, Arnesen H, Nenseter MS. Plasma homocysteine concentration related to diet, endothelial function and mononuclear cell gene expression among male hyperlipidaemic smokers. Eur J Clin Invest 1999; 29: 100-8.
73. Ikeda U, Ikeda M, Minota S, Shimada K. Homocysteine increases nitric oxide synthesis in cytokine-stimulated vascular smooth muscle cells. Circulation 1999; 99: 1230-5.
74. 2 acts synergistically to enhance mitochondrial damage. J Biol Chem 1998; 273: 30808-17.
75. Chacko G, Ling Q, Hajjar KA. Induction of acute translational response genes by homocysteine. Elongation factors-1α, -β, and-δ. J Biol Chem 1998; 273: 19840-6.
76. Chambers JC, McGregor A, Jean-Marie J, Obeid O A, Kooner J S. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia. An effect reversible with vitamin C therapy. Circulation 1999; 99: 1156-60.
77. Bellamy MF, McDowell IFW, Ramsey MW, et al. Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. Circulation 1998; 98: 1848-52.
78. Loehrer FM, Angst CP, Haefeli WE, Jordan PP, Ritz R, Fowler B. Low whole-blood S adenosylmethionine and correlation between 5-methyltetrahydrofolate and homocysteine in coronary artery disease. Arterioscler Thromb Vasc Biol 1996; 16(6): 727-33.
79. Bontemps F, Van Den Berghe. Metabolism of exogenous S-adenosylmethionine in isolated rat hepatocyte suspensions: methylation of plasma-membrane phospholipids without intracellular uptake. Biochem J 1997; 327: 383-9.
80. Weber DJ, McFadden PN. Detection and characterization of a protein isoaspartyl methyltransferase which becomes trapped in the extracellular space during blood vessel injury. J Protein Chem 1997; 16(4): 257-67.
81. Weber DJ, McFadden PN. Injury-induced enzymatic methylation of aging collagen in the extracellular matrix of blood vessel. J Protein Chem 1997; 16(4): 269-81.
82. Ross R. Atherosclerosis: a defense mechanism gone awry. Am J Pathol 1993; 143: 987-1001.
83. Arnadottir M, Hultberg B, Nilsson-Ehle P, Thysell H. The effect of reduced glomerular filtration rate on plasma total homocysteine concentration. Scand J Clin Lab Invest 1996; 56: 41-6.
84. Norlund L, Grubb A, Fex G, et al. The increase of plasma homocysteine concentration with age is partly due to the deterioration of renal function as determined by plasma cystatin C. Clin Chem Lab Med 1998; 36: 175-8.
85. Jungers P, Massy ZA, Khoa TN, et al. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study. Nephrol Dial Transplant 1997; 12: 2597-602.
86. Arnadottir M, Berg AL, HegbrantJ, Hultberg B. Influence of hemodialysis on plasma total homocysteine concentration. Nephrol Dial Transplant 1999; 14: 142-6.
87. Biasioli S, Schiavon R, Petrosino L, Cavallini L, Cavalcanti G, De Fanti E. Dialysis kinetics of homocysteine and reactive oxygen species. ASAIO J 1998; 44: M423-432.
88. Ducloux D, Ruedin C, Gibey R, et al. Prevalence, determinants, and clinical significance of hyperhomocysteinemia in renal-transplant recipients. Nephrol Dial Transplant 1998; 13: 2890-3.
89. Arnadottir M, Hultberg B, Wahlberg J, Fellstrom B, Dimeny E. Serum total homocysteine concentration before and after renal transplantation. Kidney Int 1998; 54: 1380-4.
90. Arnadottir M, Hultberg B, Vladov V, Nilsson-Ehle P, Thysell H. Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients. Transplantation 1996; 61: 509-12.
91. Massy ZA, Chadefaux-Vekemans B, Chevalier A, et al. Hyperhomocysteinemia: a significant risk factor for cardiovascular disease in renal transplant recipients. Nephrol Dial Transplant 1994; 9: 1103-8.
92. Dimeny E, Hultberg B, Wahlberg J, Fellstrom B, Arnadottir M. Serum total homocysteine concentration does not predict outcome in renal transplant recipients. Clin Transplant 1998; 12(6): 563-8.
93. Refsum H, Heiland S, Ueland PM. Radioenzymic determination of homocysteine in plasma and urine. Clin Chem 1985; 31: 624-8.
94. Bostom AG, Brosnan JT, Hall B, Nadeau MR, Selhub J. Net uptake of plasma homocysteine by the rat kidney in vivo. Atherosclerosis 1995; 116: 59-62.
95. van Guldener C, Donker AJM, Jacobs C, Teerlink T, De Meer K, Stehouwer C D A. No net renal extraction of homocysteine in fasting humans. Kidney Int 1998; 54: 166-9.
96. Parfrey PS. Cardiac and cerebrovascular disease in chronic uremia. Am J Kidney Dis 1993; 21: 77-80.
97. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9: S16-S23.
98. Bostom AG, Shemin D, Verhoef P, et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study. Arterioscler Thromb Vasc Biol 1997; 17: 2554-8.
99. Moustapha A, Naso A, Nahlawi M, et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998; 97: 138-41.
100. Bostom AG, Gohh RY, Bausserman L, et al. Serum cystatin C as a determinant of fasting total homocysteine levels in renal transplant recipients with a normal serum creatinine. J Am Soc Nephrol 1999; 10: 164-6.
101. Fodinger M, Mannhalter C, Wolfl G, et al. Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int 1997; 52: 517-23.
102. Vychytil A, Fodinger M, Wolfl G, et al. Major determinants of hyperhomocysteinemia in peritoneal dialysis patients. Kidney Int 1998; 53: 1775-82.
103. Fodinger M, Wolfl G, Fisher G, et al. Effect of MTHFR 677C>T on plasma homocysteine levels in renal graft recipients. Kidney Int 1999; 55: 1072-80.
104. Perna AF, Ingrosso D, Zappia V, Galletti P, Capasso G, De Santo NG. Enzymatic methyl esterification of erythrocyte membrane proteins is impaired in chronic renal failure: evidence for high levels of the natural inhibitor S-adenosylhomocysteine.J Clin Invest 1993; 91: 2497-503.
105. Perna AF, Ingrosso D, De Santo NG, Galletti P, Zappia V. Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosylhomocysteine in uremia. Kidney Int 1995; 47: 247-53.
106. Perna AF, Ingrosso D, Galletti P, Zappia V, De Santo NG. Membrane protein damage and methylation reactions in chronic renal failure. Kidney Int 1996; 50: 358-66.
107. Kim E, Lowenson JD, MacLaren DC, Clarke S, Young SG. Deficiency of a protein-repair enzyme results in the accumulation of altered proteins, retardation of growth, and fatal seizures in mice. Prc Natl Acad Sci USA 1997; 94: 6132-7.
108. Perna AF, D'Aniello A, Lowenson JD, Clarke S, De Santo NG, Ingrosso D. D-aspartate content of erythrocyte membrane proteins is decreased in uremia: implications for the repair of damaged proteins. J Am Soc Nephrol 1997; 8: 95-104.
109. 13C]methionine. Kidney Int (in press).
110. Loehrer FMT, Angst CP, Brunner FP, Haefeli WE, Fowler B. Evidence for disturbed S adenosylmethionine: S-adenosylhomocysteine ratio in patients with end-stage renal failure a cause for disturbed methylation reactions? Nephrol Dial Transplant 1998; 13: 656-61.
111. Wilcken DEL, Dudman NPB, Tyrrell PA, Robertson MR. Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: possible implications for prevention of vascular disease. Metabolism 1988; 37: 697-701.
112. Arnadottir M, Brattstrom L A, Simonsen O, et al. The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Nephrol 1993; 40: 236-40.
113. Bostom AG, Shemin D, Lapane KL, et al. High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996; 49: 147-52.
114. van Guldener C, Janssen MJ, de Meer KD, Donker AJ, Stehouwer CD. Effect of folic acid and betaine on fasting and postmethionine-loading plasma homocysteine and methionine levels in chronic haemodialysis patients. J Intern Med 1999; 245: 175-83.
115. Wiklund O, Fager G, Andersson A, Lundstam U, Masson P, Hultberg B. N-acetylcysteine treatment lowers plasma homocysteine but not serum lipoprotein(a) levels. Atherosclerosis 1996; 119: 99-106.
116. Westhuyzen J, Matherson K, Tracey R, Fleming SJ. Effect of withdrawal of folk acid supplementation in maintenance hemodialysis patients. Clin Nephrol 1993; 40: 96-9.
117. Janssen MJFM, van den Berg M, van Guldener C, Boers GHJ, Stehouwer CDA. Withdrawal of folic acid supplementation in maintenance hemodialysis patients. Clin Nephrol 1994; 42: 136-7.
118. van Guldener C, Janssen MJ, Lambert J, ter Wee PM, Donker AJ, Stehouwer CD. Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: no change in endothelial function after long-term therapy. Perit Dial Int 1998; 18: 282-9.
119. van Guldener C, Janssen MJ, Lambert J, ter Wee PM, Jakobs C, Donker AJM, Stehouwer CDA. No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinemia in hemodialysis patients. Nephrol Dial Transplant 1998; 13: 106-12.
120. Perna AF, Ingrosso D, De Santo NG, Galletti P, Brunone M, Zappia V. Metabolic consequences of folate-induced reduction of hyperhomocysteinemia in uremia. J Am Soc Nephrol 1997; 8: 1899-905.
121. Herbert V, Bigauette J. Call for endorsement of a petition to the Food and Drug Administration to always add vitamin B-12 to any folate fortification or supplement. Am J Clin Nutr 1997; 65: 572-3.